Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Journal of Hematology & Oncology|April 10, 2026
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meetingRong Wei, Shenmiao YangBlood Reviews|September 7, 2021
Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cellsShenmiao Yang, Xiaojun Huang, Robert Peter GaleJournal of Clinical Medicine|July 2, 2021
Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?Shenmiao Yang, Xiaojun Huang, Robert Peter GaleAnnals of Hematology|January 4, 2020
The prognostic significance of ΔSUVmax assessed by PET/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin's lymphomaShenmiao Yang, Liheng Qiu, Xiaojun Huang, et al.Journal of Cancer Research and Clinical Oncology|October 20, 2020
Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphomaShenmiao Yang, Dong Dong, Hongfei Gu, et al.Acta Haematologica|September 27, 2021
Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus ReactivationShenmiao Yang, Rong Zhu, Nan Li, et al.Health and Quality of Life Outcomes|April 9, 2020
Validation of the Chinese EORTC chronic lymphocytic leukaemia module - application of classical test theory and item response theoryDong Dong, Jun Jin, Simone Oerlemans, et al.Annals of Hematology|July 1, 2023
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemiaShenmiao Yang, Nan Li, Rong Zhu, et al.Frontiers in Oncology|June 5, 2024
The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemiaShenmiao Yang, Rong Wei, Hongxia Shi, et al.Leukemia Research|September 4, 2018
Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?Shenmiao Yang, Robert Peter Gale, Hongxia Shi, et al.Pageof 4